This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Partnering, Business Development & Licensing
BIO-Europe 2017 Interviews

BIO-Europe® 2017: Axial CEO on microbiome use against autism

Posted by on 21 November 2017
Share this article

David Donabedian, CEO of Axial Biotherapeutics, chats with Mike Ward, head of content for Informa Pharma Insights, about using the microbiome to treat autism and why this R&D area is not just a passing phase. The pair discusses Axial’s technology, as well as the next steps for the emerging biotech which will enter the clinic in 2018. Axial is focused on the link between the human gut microbiome and the central nervous system; with its first clinical-stage asset the company is targeting patients with autism.

Share this article

Sign up for Partnering, Business Development & Licensing email updates